S&P 500   4,370.55 (-0.90%)
DOW   34,312.82 (-0.15%)
QQQ   346.23 (-2.00%)
AAPL   159.69 (-1.19%)
MSFT   291.34 (-1.70%)
FB   302.84 (-1.90%)
GOOGL   2,558.99 (-2.18%)
AMZN   2,800.63 (-3.12%)
TSLA   924.49 (-0.59%)
NVDA   224.29 (-4.03%)
BABA   118.75 (-1.35%)
NIO   23.76 (-4.46%)
AMD   111.92 (-3.96%)
CGC   7.25 (-2.03%)
MU   81.26 (-2.04%)
GE   90.33 (-6.79%)
T   26.36 (+0.08%)
F   19.87 (-2.55%)
DIS   135.60 (-1.35%)
AMC   16.23 (-2.46%)
PFE   52.56 (+1.98%)
ACB   4.14 (-4.17%)
BA   201.84 (-1.16%)
S&P 500   4,370.55 (-0.90%)
DOW   34,312.82 (-0.15%)
QQQ   346.23 (-2.00%)
AAPL   159.69 (-1.19%)
MSFT   291.34 (-1.70%)
FB   302.84 (-1.90%)
GOOGL   2,558.99 (-2.18%)
AMZN   2,800.63 (-3.12%)
TSLA   924.49 (-0.59%)
NVDA   224.29 (-4.03%)
BABA   118.75 (-1.35%)
NIO   23.76 (-4.46%)
AMD   111.92 (-3.96%)
CGC   7.25 (-2.03%)
MU   81.26 (-2.04%)
GE   90.33 (-6.79%)
T   26.36 (+0.08%)
F   19.87 (-2.55%)
DIS   135.60 (-1.35%)
AMC   16.23 (-2.46%)
PFE   52.56 (+1.98%)
ACB   4.14 (-4.17%)
BA   201.84 (-1.16%)
S&P 500   4,370.55 (-0.90%)
DOW   34,312.82 (-0.15%)
QQQ   346.23 (-2.00%)
AAPL   159.69 (-1.19%)
MSFT   291.34 (-1.70%)
FB   302.84 (-1.90%)
GOOGL   2,558.99 (-2.18%)
AMZN   2,800.63 (-3.12%)
TSLA   924.49 (-0.59%)
NVDA   224.29 (-4.03%)
BABA   118.75 (-1.35%)
NIO   23.76 (-4.46%)
AMD   111.92 (-3.96%)
CGC   7.25 (-2.03%)
MU   81.26 (-2.04%)
GE   90.33 (-6.79%)
T   26.36 (+0.08%)
F   19.87 (-2.55%)
DIS   135.60 (-1.35%)
AMC   16.23 (-2.46%)
PFE   52.56 (+1.98%)
ACB   4.14 (-4.17%)
BA   201.84 (-1.16%)
S&P 500   4,370.55 (-0.90%)
DOW   34,312.82 (-0.15%)
QQQ   346.23 (-2.00%)
AAPL   159.69 (-1.19%)
MSFT   291.34 (-1.70%)
FB   302.84 (-1.90%)
GOOGL   2,558.99 (-2.18%)
AMZN   2,800.63 (-3.12%)
TSLA   924.49 (-0.59%)
NVDA   224.29 (-4.03%)
BABA   118.75 (-1.35%)
NIO   23.76 (-4.46%)
AMD   111.92 (-3.96%)
CGC   7.25 (-2.03%)
MU   81.26 (-2.04%)
GE   90.33 (-6.79%)
T   26.36 (+0.08%)
F   19.87 (-2.55%)
DIS   135.60 (-1.35%)
AMC   16.23 (-2.46%)
PFE   52.56 (+1.98%)
ACB   4.14 (-4.17%)
BA   201.84 (-1.16%)
OTCMKTS:IPHYF

Innate Pharma Stock Forecast, Price & News

$3.86
-0.39 (-9.18%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.78
$3.86
50-Day Range
$3.86
$5.20
52-Week Range
$3.15
$11.00
Volume
300 shs
Average Volume
833 shs
Market Capitalization
$303.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.44
30 days | 90 days | 365 days | Advanced Chart
Receive IPHYF News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.


Innate Pharma logo

About Innate Pharma

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Headlines

Innate Pharma 2022 Financial Calendar
October 26, 2021 |  finance.yahoo.com
What Is Happening With Innate Pharma Stock On Friday?
September 17, 2021 |  finance.yahoo.com
Here's Why Innate Pharma Stock Is Rocketing Higher Today
September 17, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IPHYF
Previous Symbol
NASDAQ:IPHYF
Employees
244
Year Founded
N/A

Sales & Book Value

Annual Sales
$80.47 million
Cash Flow
$0.47 per share
Book Value
$2.27 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$303.16 million
Optionable
Not Optionable

Company Calendar

Today
1/25/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

Is Innate Pharma a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Innate Pharma stock.
View analyst ratings for Innate Pharma
or view top-rated stocks.

How has Innate Pharma's stock been impacted by Coronavirus?

Innate Pharma's stock was trading at $7.1690 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IPHYF shares have decreased by 46.2% and is now trading at $3.86.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Innate Pharma?

Innate Pharma saw a increase in short interest in December. As of December 31st, there was short interest totaling 13,700 shares, an increase of 407.4% from the December 15th total of 2,700 shares. Based on an average trading volume of 2,700 shares, the short-interest ratio is currently 5.1 days.
View Innate Pharma's Short Interest
.

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the following people:
  • Mondher Mahjoubi, Chairman-Executive Board & Chief Executive Officer
  • Odile Belzunce, Senior VP-Compliance, IT & Operations
  • Frederic Lombard, Chief Financial Officer
  • Eric Vivier, Chief Scientific Officer & Senior Vice President
  • Joyson Joseph Karakunnel, Chief Medical Officer & Executive Vice President

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

How do I buy shares of Innate Pharma?

Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innate Pharma's stock price today?

One share of IPHYF stock can currently be purchased for approximately $3.86.

How much money does Innate Pharma make?

Innate Pharma has a market capitalization of $303.16 million and generates $80.47 million in revenue each year.

How many employees does Innate Pharma have?

Innate Pharma employs 244 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is www.innate-pharma.com.

Where are Innate Pharma's headquarters?

Innate Pharma is headquartered at 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at (343) 030-3030, via email at [email protected], or via fax at 33-04-30-30-30-00.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.